Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05136404 · ClinicalTrials.gov registry record · Phase 1
A Relative Bioavailability Study of Selpercatinib (LY3527723) in Healthy Participants
A Phase 1 study, sponsored by Loxo Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT05136404 is a Phase 1 study that has completed, run by Loxo Oncology. The registered enrollment target is 42 participants.
The verdict
NCT05136404, a Phase 1 study, has completed, sponsored by Loxo Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
The main purpose of this study is to compare the amount of selpercatinib that gets into the blood stream and how long it takes the body to get rid of it, when given as three different formulations in adult healthy participants. The information about any adverse effects experienced will be collected and the tolerability of selpercatinib will also be evaluated. The study may last up to 59 days including the 28 days of screening period.
Interventions
- DRUG Selpercatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2021-12-03 |
| Est. Completion | 2022-03-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05136404
The ClinicalTrials.gov registry entry for NCT05136404 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Loxo Oncology, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Selpercatinib is the first listed.
NCT05136404 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05136404 about?
NCT05136404 is a clinical study titled "A Relative Bioavailability Study of Selpercatinib (LY3527723) in Healthy Participants". The main purpose of this study is to compare the amount of selpercatinib that gets into the blood stream and how long it takes the body to get rid of it, when given as three different formulations in adult healthy participants. The information about any adverse effects experienced will be collected ...
What is the current status of trial NCT05136404?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2021-12-03. Estimated completion is 2022-03-14.
What interventions are being tested in trial NCT05136404?
The interventions under investigation include: Selpercatinib (DRUG).
Who is sponsoring clinical trial NCT05136404?
This trial is sponsored by Loxo Oncology, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.